Search

Ellen R Bosl

from Saint Paul, MN
Age ~45
Get Report
Also known as:
Ellen Rose Bosl, Ellen R Greden
Related to:
Linda Y Huang, 46Marshall MillerMichelle Miller, 46Lara Greden, 47June Miller
Connected to:
Kelli Bosland, 32Fabian A Bosler, 63Lynn M Bosler, 86Mark W Boslett, 65Aaron D Bosley, 54Angela L Bosley, 53Audra J Bosley, 48Bill J Bosley, 47Bridget L Bosley, 59Cheylynne Y Bosley, 41

Ellen Bosl Phones & Addresses

  • Saint Paul, MN
  • Hinckley, MN
  • Minneapolis, MN
  • 3210 Black Oak Dr, Eagan, MN 55121

Work

Company: 3m health care Position: Senior director research and development

Education

Degree: Masters School / High School: University of St. Thomas 2005 to 2008 Specialities: Management

Skills

Product Development • Cross Functional Team Leadership • Project Management • Management • Technology Commercialization • Collaborative Innovation • Technical Leadership • Technical Product Management • Engineering • Technology Development • Design of Experiments • Technology Management • R&D

Ranks

Certificate: Leading Strategic Growth: Executive Education Program With Columbia Business School and Execonline, Inc.

Interests

Science and Technology • Social Services • Economic Empowerment

Industries

Mechanical Or Industrial Engineering

Resumes

Resumes

Ellen Bosl Photo 1

Senior Director Research And Development

View page
Location:
Saint Paul, MN
Industry:
Mechanical Or Industrial Engineering
Work:
3M Health Care
Senior Director Research and Development
Education:
University of St. Thomas 2005 - 2008
Masters, Management University of Minnesota 1997 - 2001
Bachelors, Bachelor of Science, Chemical Engineering
Skills:
Product Development
Cross Functional Team Leadership
Project Management
Management
Technology Commercialization
Collaborative Innovation
Technical Leadership
Technical Product Management
Engineering
Technology Development
Design of Experiments
Technology Management
R&D
Interests:
Science and Technology
Social Services
Economic Empowerment
Certifications:
Leading Strategic Growth: Executive Education Program With Columbia Business School and Execonline, Inc.
Columbia Business School

Publications

Us Patents

Optical Films Incorporating Cyclic Olefin Copolymers

View page
US Patent:
7348066, Mar 25, 2008
Filed:
Oct 14, 2005
Appl. No.:
11/250933
Inventors:
Bert T. Chien - St. Paul MN, US
Joan M. Strobel - Maplewood MN, US
Mark A. Strobel - Maplewood MN, US
Clinton L. Jones - Somerset WI, US
Joel A. Getschel - Osceola WI, US
Ellen R. Bosl - Eagan MN, US
Assignee:
3M Innovative Properties Company - St. Paul MN
International Classification:
B32B 27/08
US Classification:
428517, 428519, 428520, 428521, 428522, 428523
Abstract:
A norbornene-based cyclic olefin layer with a curable layer disposed thereon is described. The curable layer may additionally be imparted with a texture. The norbornene-based cyclic olefin films with curable layers can be incorporated into optical bodies which include an optical film, such as an oriented multilayer optical film. In addition, the invention includes a method of coating a curable layer onto a norbornene-based polymer layer or film without requiring a primer layer. Methods of making the norbornene-based cyclic olefin layer containing films are also disclosed.

Abuse-Resistant Transdermal Dosage Form

View page
US Patent:
20040219195, Nov 4, 2004
Filed:
Dec 23, 2003
Appl. No.:
10/744966
Inventors:
John Hart - Stillwater MN, US
Steven Anderson - Vadnais Heights MN, US
Melissa Vanblaricom - Hudson WI, US
Ellen Bosl - Eagan MN, US
Assignee:
3M Innovative Properties Company
International Classification:
A61F013/00
US Classification:
424/449000, 604/180000
Abstract:
The present invention comprises a transdermal dosage form comprising an active agent component having a skin contacting surface, an adverse agent component, and a barrier. The dosage form comprises at least one channel passing between proximal and distal surfaces of the active agent component. The barrier is interposed between the active agent component and the adverse agent component. In one aspect, the barrier is permeable to selected solvents and impermeable to diffusion of active and adverse agents in the absence of said solvent. In another aspect, the barrier is discontinuous, impermeable to diffusion of active and adverse agents, and the dosage form comprises at least one channel passing between the skin-contacting surface and the adverse agent component.

Optical Films Incorporating Cyclic Olefin Copolymers

View page
US Patent:
20060093845, May 4, 2006
Filed:
Oct 29, 2004
Appl. No.:
10/976675
Inventors:
Bert Chien - St. Paul MN, US
Joan Strobel - Maplewood MN, US
Mark Strobel - Maplewood MN, US
Clinton Jones - Somerset WI, US
Joel Getschel - Osceola WI, US
Ellen Bosl - Eagan MN, US
International Classification:
B32B 27/08
US Classification:
428520000, 428523000, 428522000, 427569000
Abstract:
A norbomene-based cyclic olefin layer with a curable layer disposed thereon is described. The curable layer may additionally be imparted with a texture. The norbomene-based cyclic olefin films with curable layers can be incorporated into optical bodies which include an optical film, such as an oriented multilayer optical film. In addition, the invention includes a method of coating a curable layer onto a norbomene-based polymer layer or film without requiring a primer layer. Methods of making the norbomene-based cyclic olefin layer containing films are also disclosed.

Optical Films Incorporating Cyclic Olefin Copolymers

View page
US Patent:
20060159888, Jul 20, 2006
Filed:
Oct 14, 2005
Appl. No.:
11/250765
Inventors:
Timothy Hebrink - Scandia MN, US
Joan Strobel - Maplewood MN, US
Barry Rosell - Lake Elmo MN, US
Kevin Hamer - St. Paul MN, US
Kristopher Derks - Woodbury MN, US
Robert Taylor - Stacy MN, US
Ronald Borst - Hastings MN, US
Ellen Bosl - Eagan MN, US
Bert Chien - St. Paul MN, US
Carsten Franke - St. Paul MN, US
Gregg Patnode - Woodbury MN, US
Kevin Schaffer - Woodbury MN, US
International Classification:
G11B 5/64
US Classification:
428141000
Abstract:
The present disclosure relates to optical bodies including one or more norbornene-based cyclic olefin film layers and one or more rough strippable skin layers operatively connected to a surface of the norbornene-based cyclic olefin film layer. The rough strippable skin layer comprises a continuous phase and a disperse phase. Methods of producing such optical bodies are also disclosed.

Optical Films Incorporating Cyclic Olefin Copolymers

View page
US Patent:
20080152837, Jun 26, 2008
Filed:
Feb 28, 2008
Appl. No.:
12/039522
Inventors:
Bert T. Chien - St. Paul MN, US
Joan M. Strobel - Maplewood MN, US
Mark A. Strobel - Maplewood MN, US
Clinton L. Jones - Somerset WI, US
Joel A. Getschel - Osceola WI, US
Ellen R. Bosl - Eagan MN, US
International Classification:
B05D 3/00
US Classification:
427536
Abstract:
A norbornene-based cyclic olefin layer with a curable layer disposed thereon is described. The curable layer may additionally be imparted with a texture. The norbornene-based cyclic olefin films with curable layers can be incorporated into optical bodies which include an optical film, such as an oriented multilayer optical film. In addition, the invention includes a method of coating a curable layer onto a norbornene-based polymer layer or film without requiring a primer layer. Methods of making the norbornene-based cyclic olefin layer containing films are also disclosed.

Abuse-Resistant Transdermal Dosage Form

View page
US Patent:
20100068249, Mar 18, 2010
Filed:
Nov 19, 2009
Appl. No.:
12/621595
Inventors:
John R. Hart - Stillwater MN, US
Steven C. Anderson - Vadnais Heights MN, US
Melissa A. Vanblaricom - Hudson WI, US
Ellen R. Bosl - Eagan MN, US
International Classification:
A61K 31/445
A61K 9/70
A61P 25/00
US Classification:
424448, 424449, 514329
Abstract:
The present invention comprises a transdermal dosage form comprising an active agent component having a skin contacting surface, an adverse agent component, and a barrier. The dosage form comprises at least one channel passing between proximal and distal surfaces of the active agent component. The barrier is interposed between the active agent component and the adverse agent component. In one aspect, the barrier is permeable to selected solvents and impermeable to diffusion of active and adverse agents in the absence of said solvent. In another aspect, the barrier is discontinuous, impermeable to diffusion of active and adverse agents, and the dosage form comprises at least one channel passing between the skin-contacting surface and the adverse agent component.
Control profile
Ellen R Bosl from Saint Paul, MN, age ~45 Get Report